X0607 3 2026-07-31 0 0001710340 Eton Pharmaceuticals, Inc. ETON 0002149737 Radosavljevic Danka false C/ ETON PHARMACEUTICALS, INC. 21925 W. FIELD PARKWAY, SUITE 235 DEERPARK IL 60010 0 1 0 0 Chief Operating Officer Common Stock 22473 D Employee Stock Option (Right to Buy) 15.47 2036-01-11 Common Stock 31508 D Restricted Stock Units 0 Common Stock 20039 D Restricted Stock Units 0 Common Stock 7194 D Employee Stock Option (Right to Buy) 13 2035-01-02 Common Stock 14317 D Employee Stock Option (Right to Buy) 14.68 2035-03-17 Common Stock 10000 D Employee Stock Option (Right to Buy) 4.42 2034-02-12 Common Stock 92993 D Employee Stock Option (Right to Buy) 4.74 2033-08-14 Common Stock 10000 D Employee Stock Option (Right to Buy) 3.47 2033-02-19 Common Stock 42224 D Employee Stock Option (Right to Buy) 8.61 2031-05-02 Common Stock 35000 D Employee Stock Option (Right to Buy) 3.58 2030-03-11 Common Stock 60000 D Employee Stock Option (Right to Buy) 1.38 2027-07-23 Common Stock 18742 D Common Stock 0 Common Stock 128985 D The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030. The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 3, 2029. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on March 18, 2029. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 13, 2028. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on August 15, 2027. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2027. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on May 3, 2025. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on March 12, 2024. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on July 24, 2021. On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029. The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. The reporting person has authorized and designated the named person to file this Form 3 on the reporting person's behalf for indefinite duration. /s/ Judith Matthews 2026-08-12